Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old

· Issued by Vertex Pharmaceuticals Incorporated

On 6ix: 6ix.com/news/european-commission-approves-orkambir-lumacaftor-ivacaftor-for-the-treatment-of

Watch Vertex Pharmaceuticals explain itVertex Pharmaceuticals (NASDAQ:VRTX) Q2 2023 Earnings Call · Replay · Aug 1, 2023 · From 5:06 · Cystic Fibrosis Portfolio and R&D Updates
Vertex Pharmaceuticals' next earnings callVertex Pharmaceuticals (NASDAQ:VRTX) Q3 2026 Earnings Call · Nov 2, 2026 at 4:30 PM ESTRegister

-Nearly 300 children with cystic fibrosis and two copies of the F508del mutation are now eligible for the first time for a medicine that can treat the underlying cause of their disease-

LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label extension of ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) ages 1 to

Vertex Pharmaceuticals Incorporated on 6ix

Story so far

Earlier from Vertex Pharmaceuticals

Later from Vertex Pharmaceuticals

All Vertex Pharmaceuticals news releases